 SR: favorable cytogenetics without associated high-risk abnormalities and in CR after cycle 1 or intermediate-risknormal cytogenetics without FLT3 mutation andor without any one additional clinical risk factors, i.e. total WBC 50x10e9l, FAB subtype M0, M6 or M7, prior myelodysplasia or secondary AML,hepatosplenomegaly, late CR cycle 2. 